Analyst Consensus ?
ConsensusBuy19 ratings
Bullish1157.9%
Neutral842.1%
Bearish00.0%
GE HealthCare Technologies Inc. · GEHC · FY2026 Q3 · Calendar Q4 2026
GE HealthCare raises 2026 outlook as margins expand
GE HealthCare’s Q3 supports a constructive operating trajectory: organic growth and margin expansion led management to raise 2026 guidance. The outlook still depends on capital-equipment demand, radiopharmaceutical execution and supply-chain cost control.
Reported Before market openNASDAQHealthcare
$32.12B market cap
80quality score
Earnings scorecard
Reported versus consensus
Reported EPS
—
Consensus $1.20
EPS surprise
—
Reported versus consensus
Reported revenue
—
Consensus $5.35B
Revenue surprise
—
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
+6.6%
Event window
SPY move
+0.3%
Same window
Abnormal move
+6.3%
Stock minus SPY
Volume
2.8×
Versus trailing sessions
Subsequent drift
0.0%
Up to 20 sessions
GEHCSPY benchmark
Ask FN2 about GEHC FY2026 Q3
Transcript, numbers and history already loaded
What drove GEHC's +6.6% move after FY2026 Q3 earnings?What changed in GEHC's guidance and outlook in FY2026 Q3?Give me the bull and bear case for GEHC after FY2026 Q3 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Management raised full-year 2026 guidance to approximately 4% organic revenue growth and a 15.5%–15.7% EBIT margin range. The quarter also featured CE marking for PhotoNova Spectra, pending FDA clearance for Starguide GX and the planned SoFi Bioscience acquisition.
Guidance delta
Raised: full-year 2026 organic revenue growth to approximately 4% and EBIT margin to 15.5%–15.7%.
Key takeaways
- Q3 organic revenue growth was 6.2%, while adjusted EBIT margin expanded 180 basis points to 16.6%.
- Radiopharmaceuticals, AI-enabled imaging and ultrasound were identified as growth areas; SoFi Bioscience is intended to strengthen radiopharmaceutical manufacturing.
- The backlog was $23.7 billion, while book-to-bill was 1.03x, keeping capital-equipment demand and backlog volatility in focus.
Management priorities
- Execute the Heartbeat operating framework to improve productivity and supply-chain resilience.
- Advance PhotoNova Spectra, Starguide GX and AI-enabled imaging and ultrasound platforms.
- Scale Vercado and integrate SoFi Bioscience capabilities within the radiopharmaceutical business.
Follow GEHC with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$75.82Current
$65Low
$86.23Average
$110High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 29, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| BTIG | Buy | Buy | Maintain | Oct 12, 2026 |
| Needham | Buy | Buy | Maintain | Oct 5, 2026 |
| Citigroup | Neutral | Neutral | Maintain | Oct 5, 2026 |
| UBS | Neutral | Neutral | Maintain | Jul 31, 2026 |
| Wells Fargo | Overweight | Overweight | Maintain | Jul 30, 2026 |
| Evercore ISI Group | Outperform | Outperform | Maintain | Jul 30, 2026 |
| JP Morgan | Neutral | Neutral | Maintain | Apr 30, 2026 |
| Goldman Sachs | Neutral | Buy | Downgrade | Apr 30, 2026 |
| Barclays | Equal Weight | Equal Weight | Maintain | Apr 30, 2026 |
| Piper Sandler | Overweight | Overweight | Maintain | Apr 17, 2026 |
| Mizuho | Outperform | Outperform | Maintain | Apr 13, 2026 |
| Stifel | Buy | Buy | Maintain | Feb 5, 2026 |
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | Feb 5, 2026 |
| B of A Securities | Neutral | Neutral | Maintain | Jan 5, 2026 |
| Jefferies | Buy | Buy | Maintain | Dec 11, 2025 |
| Argus Research | Buy | Buy | Maintain | Apr 1, 2024 |
| Oppenheimer | Outperform | Outperform | Maintain | May 16, 2023 |
| Redburn Partners | Buy | Buy | Maintain | Jan 19, 2023 |
| Edward Jones | Hold | Hold | Maintain | Jan 4, 2023 |
Named analyst price targets
Upside is calculated against the persisted current price $75.82. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Barclays | Analyst unavailable | $85 | $64.77 | +12.1% | Oct 6, 2026 |
| Needham | Analyst unavailable | $93 | $64.81 | +22.7% | Sep 22, 2026 |
| Evercore ISI | Analyst unavailable | $84 | $69.06 | +10.8% | Jul 30, 2026 |
| BTIG | Analyst unavailable | $79 | $71.54 | +4.2% | Jul 29, 2026 |
| UBS | Analyst unavailable | $67 | $64.23 | -11.6% | Jul 16, 2026 |
| BTIG | Ryan Zimmerman | $75 | $64.7 | -1.1% | Jul 13, 2026 |
| BMO Capital | Analyst unavailable | $70 | $64.68 | -7.7% | Jul 8, 2026 |
| RBC Capital | Analyst unavailable | $80 | $60.64 | +5.5% | Jun 23, 2026 |
| UBS | Graham Doyle | $69 | $64.26 | -9.0% | May 21, 2026 |
| Evercore ISI | Analyst unavailable | $80 | $59.81 | +5.5% | Apr 30, 2026 |
| Oppenheimer | Suraj Kalia | $85 | $60.04 | +12.1% | Apr 30, 2026 |
| Barclays | Matt Miksic | $78 | $59.48 | +2.9% | Apr 30, 2026 |
| Goldman Sachs | David Roman | $65 | $59.48 | -14.3% | Apr 30, 2026 |
| Stifel Nicolaus | Analyst unavailable | $80 | $60.06 | +5.5% | Apr 29, 2026 |
| Piper Sandler | Analyst unavailable | $88 | $73.2 | +16.1% | Apr 17, 2026 |
| Mizuho Securities | Analyst unavailable | $90 | $72.69 | +18.7% | Apr 13, 2026 |
| Barclays | Analyst unavailable | $87 | $82.31 | +14.7% | Feb 6, 2026 |
| Stifel Nicolaus | Rick Wise | $98 | $82.63 | +29.3% | Feb 4, 2026 |
| Morgan Stanley | Analyst unavailable | $85 | $82.63 | +12.1% | Feb 4, 2026 |
| BTIG | Ryan Zimmerman | $91 | $83.7 | +20.0% | Feb 4, 2026 |
| Piper Sandler | Analyst unavailable | $94 | $78.78 | +24.0% | Jan 30, 2026 |
| UBS | Analyst unavailable | $77 | $85.3 | +1.6% | Jan 15, 2026 |
| Goldman Sachs | Analyst unavailable | $98 | $88.16 | +29.3% | Jan 9, 2026 |
| Stifel Nicolaus | Analyst unavailable | $95 | $86.73 | +25.3% | Jan 7, 2026 |
| Evercore ISI | Analyst unavailable | $95 | $84.2 | +25.3% | Jan 5, 2026 |
| Jefferies | Analyst unavailable | $105 | $85.54 | +38.5% | Dec 11, 2025 |
| Stifel Nicolaus | Rick Wise | $90 | $76.29 | +18.7% | Nov 21, 2025 |
| Wells Fargo | Larry Biegelsen | $87 | $77.38 | +14.7% | Oct 30, 2025 |
| BTIG | Analyst unavailable | $87 | $77.38 | +14.7% | Oct 29, 2025 |
| BTIG | Ryan Zimmerman | $89 | $71.01 | +17.4% | Oct 13, 2025 |
| Barclays | Analyst unavailable | $86 | $71.01 | +13.4% | Oct 13, 2025 |
| Morgan Stanley | Analyst unavailable | $74 | $74 | -2.4% | Sep 18, 2025 |
| UBS | Graham Doyle | $73 | $69.37 | -3.7% | May 5, 2025 |
| BTIG | Ryan Zimmerman | $95 | $64.39 | +25.3% | Apr 14, 2025 |
| Piper Sandler | Jason Bednar | $97 | $82.08 | +27.9% | Nov 15, 2024 |
| UBS | Graham Doyle | $74 | $93.01 | -2.4% | Sep 26, 2024 |
| Bank of America Securities | Craig Bijou | $97 | $90.62 | +27.9% | Sep 20, 2024 |
| BTIG | Ryan Zimmerman | $100 | $86.79 | +31.9% | Sep 18, 2024 |
| Goldman Sachs | David Roman | $87 | $78.45 | +14.7% | May 30, 2024 |
| Piper Sandler | Jason Bednar | $92 | $81.5 | +21.3% | May 21, 2024 |
| Mizuho Securities | Anthony Petrone | $105 | $77.74 | +38.5% | May 1, 2024 |
| Evercore ISI | Vijay Kumar | $96 | $76.24 | +26.6% | Apr 30, 2024 |
| Mizuho Securities | Anthony Petrone | $110 | $85.39 | +45.1% | Apr 11, 2024 |
| Argus Research | David Toung | $110 | $90.91 | +45.1% | Apr 1, 2024 |
| UBS | Graham Doyle | $88 | $83.17 | +16.1% | Feb 12, 2024 |
| Morgan Stanley | Patrick Wood | $76 | $77.17 | +0.2% | Jun 27, 2023 |
| Oppenheimer | Suraj Kalia | $97 | $77 | +27.9% | May 16, 2023 |
Track every rating change on GEHC the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationGE HealthCare Technologies Inc. is a global medical technology company that creates, manufactures, and markets a diverse range of medical devices, services, and integrated digital solutions. These offerings are designed to assist in the diagnosis, treatment, and ongoing monitoring of patients. The company boasts an extensive international presence, serving markets across the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, and Hong Kong, among other regions. Its operations are structured across four primary business divisions: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging division specializes in advanced diagnostic imaging technologies, including systems for molecular imaging, Computed Tomography (CT) scans, Magnetic Resonance (MR) imaging, image-guided therapy, and X-ray, alongside specialized women's health products.…
Historical context
All GEHC earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| LH Labcorp Holdings Inc. | FY2026 Q3 · Calendar Q4 2026 | — | +8.8% | Labcorp raises 2026 outlook as Q3 growth broadens |
| BIIB Biogen Inc. | FY2026 Q3 · Calendar Q4 2026 | — | -3.4% | Biogen Q3: Growth portfolio expands as guidance rises |
| UHS Universal Health Services, Inc. | FY2026 Q3 · Calendar Q4 2026 | +0.6% | -2.9% | UHS reaffirms guidance as new-hospital ramps weigh on Q3 |
| GSK GSK plc | FY2026 Q3 · Calendar Q4 2026 | — | -4.3% | GSK reaffirms 2026 guidance as specialty medicines drive Q3 growth |
| BSX Boston Scientific Corporation | FY2026 Q3 · Calendar Q4 2026 | — | -3.5% | BSX Holds 2026 Guide Despite Cyber Hit and EP Pressure |
| AVTR Avantor, Inc. | FY2026 Q3 · Calendar Q4 2026 | — | -2.2% | Avantor reports stronger growth and raises full-year guidance |
Latest beats and misses
Who reports nextBeat on EPS
- EXEFY2026 Q3 · October 27, 2026+13.2% EPS-3.2% move
- CRFY2026 Q3 · October 27, 2026+12.6% EPS+2.9% move
- PPGFY2026 Q3 · October 27, 2026+6.1% EPS+4.4% move
- UMBFFY2026 Q3 · October 27, 2026+10.6% EPS-1.1% move
- UHSFY2026 Q3 · October 27, 2026+0.6% EPS-2.9% move
- ACGLNFY2026 Q3 · October 27, 2026+15.6% EPS-0.9% move
Get the GEHC recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-10-28T16:04:19.378264+00:00
- FN2 earnings calendar · 2026-10-28T01:23:13.546025+00:00
- Polygon adjusted daily market bars · 2026-10-29T00:30:43.715811+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-29T00:30:43.713147+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-29. For educational purposes only; not investment advice.